Literature DB >> 16960925

Posterior reversible encephalopathy syndrome--an underrecognized manifestation of systemic lupus erythematosus.

Jason K Kur1, John M Esdaile.   

Abstract

OBJECTIVE: Posterior reversible encephalopathy syndrome (PRES) is a rare, recently described neurologic condition identifiable by clinical presentation and magnetic resonance image (MRI) appearance. It is associated with renal insufficiency, hypertension, and rheumatologic diseases. Patients present with headache, seizures, loss of vision and altered mental function, and a pattern on imaging studies of predominantly transient, posterior cerebral hyperintensities on T2-weighted MRI. There is a high likelihood of presentation of this syndrome to a rheumatologist.
METHODS: Three recent cases of systemic lupus erythematosus (SLE) with PRES, along with 9 previously reported cases, are reviewed.
RESULTS: All 3 patients presented with seizures and subacute visual changes in association with lupus nephritis. The first presented with hypertension, complete visual field loss, and status epilepticus 2 weeks after starting oral cyclosporine therapy for refractory lupus nephritis. The second patient was normotensive and presented with seizures and visual symptoms while in hospital with SLE-related pancreatitis and nephritis. The third patient had headache and seizures with severe lupus disease activity including nephritis, pancytopenia, and pulmonary hemorrhage. Cranial MRI showed predominantly posterior signal abnormalities on T2-weighted images, which resolved after cessation of cyclosporine in the first case, treatment with IV cyclophosphamide in the second case, and treatment with cyclophosphamide and plasmapheresis in the final case. Literature review showed that PRES is a manifestation of SLE or a consequence of therapy with calcineurin inhibitors or rituximab. The hallmark features are visual loss and seizures. Severe hypertension (> 170/110 mm Hg) and renal failure were present in the majority of previously identified cases of SLE and PRES. Our second case was normotensive but had marked lupus disease activity. PRES can lead to cerebral infarction.
CONCLUSION: With increasing availability of MRI, PRES will be identified more frequently. Swift action to identify potential offending agents, controlling hypertension, and treating active disease can lead to reversal of radiologic and neurologic findings.

Entities:  

Mesh:

Year:  2006        PMID: 16960925

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  19 in total

1.  Posterior reversible encephalopathy syndrome coexists with acute cerebral infarction: challenges of blood pressure management.

Authors:  Luji Liu; Lihong Zhang
Journal:  Quant Imaging Med Surg       Date:  2020-12

Review 2.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

3.  Acute epiglottitis as the initial presentation of pediatric Systemic Lupus Erythematosus.

Authors:  Sirirat Charuvanij; Kristin M Houghton
Journal:  Pediatr Rheumatol Online J       Date:  2009-10-31       Impact factor: 3.054

4.  Posterior reversible encephalopathy syndrome in ANCA-associated vasculitis.

Authors:  Hong-Liang Zhang; Yi Yang; Jiang Wu
Journal:  Rheumatol Int       Date:  2011-07-15       Impact factor: 2.631

5.  Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.

Authors:  Jennifer E Fugate; Daniel O Claassen; Harry J Cloft; David F Kallmes; Osman S Kozak; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

6.  Differential serum cytokine profile in patients with systemic lupus erythematosus and posterior reversible encephalopathy syndrome.

Authors:  J Merayo-Chalico; A Barrera-Vargas; G Juárez-Vega; J Alcocer-Varela; A Arauz; D Gómez-Martín
Journal:  Clin Exp Immunol       Date:  2018-01-16       Impact factor: 4.330

Review 7.  Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects.

Authors:  Christie M Lincoln; Peter Fata; Susan Sotardi; Michael Pohlen; Tomas Uribe; Jacqueline A Bello
Journal:  Br J Radiol       Date:  2017-11-03       Impact factor: 3.039

8.  A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide.

Authors:  M Jabrane; Z Ait Lahcen; W Fadili; I Laouad
Journal:  Rheumatol Int       Date:  2014-11-12       Impact factor: 2.631

9.  Posterior Reversible Encephalopathy in Undiagnosed Systemic Lupus Erythematous: A Case Report.

Authors:  Wahinuddin Sulaiman; Noraini Mat Husin; Mohd Shafie Baba
Journal:  Oman Med J       Date:  2011-11

10.  Posterior reversible encephalopathy syndrome after solid organ transplantation.

Authors:  W S Bartynski; H P Tan; J F Boardman; R Shapiro; J W Marsh
Journal:  AJNR Am J Neuroradiol       Date:  2008-02-13       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.